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Chemokines in interstitial injury
Interstitial inflammation plays an important physiologic role in
many forms of progressive renal injury [1]. One critical compo-
nent of the inflammatory response is the molecules that direct the
movement of inflammatory cells. The chemokines, a family of
pro-inflammatory chemotactic cytokines, help direct the emigra-
tion of inflammatory cells into the interstitium. Recent studies
indicate that chemokines influence not only lymphocyte accumu-
lation, but they also affect interstitial biology by modulating the
activity of resident and inflammatory cells [2].
Initially, chemokines were hypothesized to play an important
role in interstitial injury because they are expressed in inflamed
kidneys [2, 3]. The ability of chemokines to mediate interstitial
injury was thought to be related to their ability to activate
integrins, which promote leukocyte adhesion to endothelial cells,
and to their chemoattractant properties. However, the chemo-
kines also mediate a myriad of other activities that may be of
equal importance. These functions include modulating the syn-
thesis of TNF-a and IL-1 by macrophages, regulating TGF-b
production, and affecting the Th1/Th2 balance during T cell
maturation [4]. These functions could have profound effects on
interstitial injury through effects on further stimulating inflamma-
tion, by promoting collagen synthesis and hence fibrosis, and by
modulating the nature of the T cell mediated immune response.
More than forty chemokines have been identified to date [5].
They group into subfamilies based upon a conserved organization
of cysteine residues. The two major subfamilies are the CXC
subfamily, in which the two amino-terminal cysteines are sepa-
rated by a single amino acid, and the CC subfamily, in which these
two cysteines are immediately adjacent. Most CC chemokines
attract monocytes/macrophages and T cells, the cell populations
that primarily comprise interstitial infiltrates.
RANTES and MCP-1, two CC chemokines, are chemoattrac-
tants for CD41 T cells and monocytes. Given the importance of
these cell populations in the propagation of interstitial nephritis,
and the fact that RANTES and MCP-1 are expressed by cytokine-
stimulated tubular cells, RANTES and MCP-1 occupy center
stage in the investigation of the role of chemokines in interstitial
injury. Consistent with this notion is the fact that they are present
in two inflammatory renal conditions that eventually develop
prominent interstitial infiltrates: allograft rejection [6, 7] and
glomerulonephritis [8, 9]. However, the presence of a cytokine
does not prove its pathogenic significance.
There are now several reports that address the functional
significance of RANTES and MCP-1. In this issue of Kidney
International, the article by Moore et al [10] examines the role of
RANTES in an autoimmune model of nephritis. This article
complements another recent publication by Lloyd et al [8] that
looks at the role of RANTES and MCP-1 in nephrotoxic serum
nephritis (NSN). Both papers show that RANTES transcript is
up-regulated in the kidney at a time consistent with it playing a
role in eliciting the interstitial infiltrates. To test RANTES’
pathogenic significance, Lloyd et al treated mice in which NSN
had been induced with a competitive antagonist of RANTES and
showed that, in spite of a significant decrease in the number of
macrophages and T cells in the interstitial infiltrate, there was no
effect on the amount of interstitial collagen. In contrast, other
experiments show that mice treated with a neutralizing antibody
to the MCP-1 not only have a decreased number of T cells and
macrophages in the interstitium to a degree comparable to that
seen with the RANTES antagonist experiments, but also have a
reduced number of glomerular crescents and decreased amount
of interstitial collagen. This suggests either that not all interstitial
inflammatory cells have an equivalent effect on renal injury, or that
MCP-1 is playing a role outside of its function as a chemoattractant.
Moore et al used a different approach to examine the in vivo
biological activity of RANTES. Instead of examining the conse-
quence of blocking RANTES, they examined the effect of ectopic
expression of RANTES. Ectopic expression was accomplished
using tubular epithelial cells that were genetically modified to
express RANTES. These cells were implanted subcapsularly into
the autoimmune MRL-lpr stain of mice as well as non-autoim-
mune C3H and MRL strain mice. In the MRL-lpr mice, the
RANTES expressing tubular epithelial cells induce large infil-
trates that are composed primarily of CD41 T cells and macro-
phages. In contrast, MRL mice had minimal infiltrates and the
C3H mice had no infiltrates. This chemokine deliver system
should prove useful in examining the role of other chemokines,
such as MCP-1, in both infiltrate formation and fibrosis.
One of the most interesting questions raised by this paper is
why the autoimmune MRL-lpr mice develop extensive infiltrates
but the congenic non-autoimmune MRL mice do not. Leukocyte
trafficking requires not only chemoattractant gradients but also
endothelial cells, which are primed for leukocyte adhesion and
leukocytes that are primed to respond to the chemoattractant
signal. Therefore, the explanation may be that there are func-
tional differences in either the leukocytes or the endothelium
between strains. It is known that adhesion molecules are up-
regulated in lpr mice, and so the difference may be a result of the
endothelial surface being receptive to leukocyte adhesion trig-
gered by the RANTES in the lpr mice. Another possibility is that,
unlike the nonautoimmune mice, the leukocytes in the autoim-
mune mice express chemokine receptors so they can respond to
the RANTES. Finally, it is possible that the difference reflects the
fact that the T cells in the autoimmune mice are reacting to
tubular antigens and this response releases cytokines/chemokines
that recruit other cells. Sorting out these possibilities should be
practical using genetically engineered mice and this ectopic
chemokine expression system.
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We are finally at a point in our understanding of the interstitial
inflammatory process that we can systematically examine the
individual components in the process. These experiments, using
various schemes to abolish the activity of a molecule or over-
express a molecule, are instrumental in precisely defining their
roles. Given the large number of chemokines that have overlap-
ping in vitro biological activities and the large number of chemo-
kine receptors with overlapping ligand specificities, it has been
feared that there is so much redundancy that no therapy directed
against a single chemokine or receptor will significantly amelio-
rate any inflammatory process. Experiments such as these, and
others using knockout mice, demonstrate two important points.
First, there is in vivo specificity to chemokine function, so therapy
directed against specific chemokines or their receptors may alter
the disease. Second, not all therapies that block inflammation may
have salutatory effects on the preservation of renal function. As
our knowledge of the many functions of the chemokines improves,
rational design of effective therapies may be possible.
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